The purpose of this survey is to provide the Canadian Cancer Survivor Network (CCSN) with insights and perspectives about the use of denosumab (Xgeva) for the prevention of skeletal-related events due to
Tag: Drug Approval
Canadians are paying the price for drug shortages, according to Canada’s hospital pharmacists, community pharmacists and physicians
OTTAWA, January 14, 2013 – According to the results of a new survey completed by over 1,070 members of the Canadian Pharmacists Association, Canadian Medical Association, and Canadian Society of Hospital Pharmacists
ZYTIGA® Now Available for Eligible Patients in Nova Scotia and Newfoundland and Labrador
Provinces are fifth and sixth in Canada to reimburse new metastatic prostate cancer treatment Toronto, ON (May 16, 2012) – Men living with metastatic prostate cancer in Nova Scotia and Newfoundland and
ZYTIGA™* (abiraterone acetate) receives Health Canada approval for treatment for metastatic prostate cancer
First Oral Treatment for Metastatic Prostate Cancer That Inhibits Androgen Production at All Three Sources Toronto, ON, July 28, 2011– Janssen Inc. announced today that after a priority review, Health Canada has
New Medication to Reduce Bone Complications Now Available in Ontario
Patients with advanced prostate cancer gain access to first-in-class treatment OTTAWA, April 25, 2012 /CNW/ – Canadian Cancer Survivor Network (CCSN) is today congratulating the Ontario government for providing access to XGEVA® (denosumab) for
Manitoba Budget 2012: Province to provide free cancer drugs for all patients
Coverage Will Eliminate Financial Burdens For Patients, Families (April 19, 2012) Premier Greg Selinger today announced the government will help support cancer patients and their families by making oral cancer drugs free